Your Client Rank:
Loading...
99
Updated 17-Mar-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 46.6% | -0.7% | -23.6% | -29.1% | | | | |
| Lilly | 17.6% | 0.3% | -6.0% | -10.2% | 9.8% | -1.3% | 29.9% | 30.5% |
| Novo | 13.4% | -0.2% | -2.8% | -2.3% | 1.6% | 0.4% | 15.2% | 16.4% |
| Daiichi | 10.9% | 1.5% | 1.8% | -4.5% | 6.8% | 0.1% | 17.5% | 17.4% |
| Vertex | 10.2% | 0.8% | -1.9% | -18.4% | 51.4% | -25.3% | >100% | >100% |
| Eisai | 8.4% | -1.3% | -2.4% | -6.7% | 10.6% | -1.5% | 19.0% | 20.3% |
| Sanofi | 6.8% | 0.9% | -3.4% | -3.2% | 5.1% | 0.8% | 10.8% | 11.5% |
| Regeneron | 6.5% | 0.2% | -1.6% | -0.8% | 2.5% | 4.8% | 8.6% | 9.2% |
| AbbVie | 6.5% | 0.3% | -3.9% | -7.6% | 4.8% | -1.0% | 12.9% | 13.0% |
| Astra | 6.0% | 0.1% | -2.2% | -1.0% | 3.4% | 0.9% | 10.6% | 10.4% |
| Roche | 4.6% | 0.2% | -1.3% | -1.2% | 1.8% | 2.9% | 6.9% | 6.7% |
| Chugai | 4.5% | 1.2% | -2.3% | -2.1% | 3.4% | -2.0% | 9.9% | 9.8% |
| JnJ | 3.5% | 0.0% | -0.9% | -2.7% | 2.7% | 0.5% | 5.0% | 6.0% |
| Teva | 3.4% | 1.7% | -8.3% | -0.2% | 2.3% | 1.1% | 8.5% | 7.8% |
| Novartis | 3.2% | 0.3% | -1.5% | 0.2% | 1.3% | 0.7% | 4.5% | 5.5% |
| Gilead | 2.9% | -0.2% | -1.8% | -10.8% | 9.9% | -5.7% | 16.2% | 16.6% |
| Amgen | 2.7% | -0.2% | -1.1% | 1.6% | -0.8% | 1.5% | 3.5% | 3.8% |
| Merck | 2.5% | -0.1% | -1.1% | -4.2% | 2.9% | 0.0% | 5.8% | 6.4% |
| Glaxo | 2.4% | 0.0% | -0.2% | 0.1% | 0.7% | 0.9% | 3.9% | 3.6% |
| Bayer | 1.3% | 1.4% | -1.8% | -1.0% | 17.2% | | 4.4% | 3.6% |
| Takeda | 1.2% | 0.5% | -1.5% | -0.4% | 13.6% | -3.8% | 2.7% | 3.1% |
| Lundbeck | 1.0% | 0.3% | -0.8% | 3.4% | 0.9% | 6.9% | -0.1% | -3.4% |
| Biogen | -0.4% | 0.4% | 0.1% | 0.0% | 1.6% | 2.0% | 1.8% | 1.7% |
| Shionogi | -1.3% | -0.7% | 2.8% | 0.4% | -3.7% | 3.2% | -4.4% | -3.4% |
| Pfizer | -2.5% | 0.0% | 0.1% | 2.4% | -0.8% | 0.5% | -3.2% | -3.5% |
| Astellas | -3.2% | -0.7% | -3.4% | 1.5% | 3.5% | 35.3% | 0.7% | 0.8% |
| Bristol | -4.4% | 0.3% | 0.9% | -14.4% | 29.0% | -21.1% | 38.7% | 39.4% |
| Neurocrine | | | | | | | | |
| EU Major | 5.5% | 0.6% | -2.2% | -1.3% | 3.7% | 0.8% | 8.8% | 8.2% |
| Other EU | 10.9% | 0.4% | -7.3% | -5.9% | 44.3% | -23.4% | >100% | |
| US Major | 4.2% | 0.3% | -2.2% | -6.7% | 6.3% | -2.2% | 11.4% | 17.4% |
| US Big Biotech | 4.1% | 0.2% | -1.8% | -6.5% | 5.8% | -2.6% | 12.3% | 11.9% |
| Other US | 3.4% | 1.7% | -8.3% | -0.2% | 2.3% | 1.1% | 8.5% | 7.8% |
| Japanese | 3.3% | 0.5% | -0.6% | -1.5% | 6.3% | 1.7% | 6.3% | 7.4% |
